Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
A recent trial showed that nicotinamide riboside supplementation might reduce airway inflammation in patients with COPD who ...
Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.
“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...
Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...
The following is a summary of “Assessing the Clinical and Functional Status of COPD Patients Using Speech Analysis During and ...
Researchers have identified new lung function and blood test cutoffs to improve timely chronic hypercapnia management in ...
Study reveals the Prospector calculator reduces antibiotic prescriptions in COPD exacerbations, improving outcomes and ...
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Patients also continue using their prescribed inhalers and medications and are advised to avoid COPD exacerbations triggered by infections or environmental factors. Early intervention for any ...